New drug targets Hard-to-Treat cancers in early trial
NCT ID NCT07601243
First seen May 24, 2026
Summary
This early-stage study tests a new drug called GS-2426 in about 174 adults with advanced solid tumors that lack a gene called MTAP. The main goal is to see if the drug is safe and to find the best dose for future studies. Participants must have tried other treatments without success or have no standard options left.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.